Overall, somatic EGFR mutations and gene copy gain mediate therapeutic resistance in HNSCC underscoring the need for newer strategies such as multitargeted kinase inhibitors or dual targeting of both the ECD and the TKD [36,43,44,45]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.